Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Genomic DNA lesions processed by nucleotide excision repair (NER) are primarily bulky, helix-distorting modifications to the DNA structure, most notably cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts (6-4PPs) induced by ultraviolet (UV) radiation (Sancar, A. 2003. Chemical Reviews). These lesions occur when adjacent pyrimidine bases covalently bond, creating a physical block that stalls DNA polymerase and RNA polymerase, leading to mutations or cell death (Marteijn, J. A., et al. 2014. Nature Reviews Molecular Cell Biology). The NER pathway is the specialized cellular machinery responsible for identifying, excising, and repairing these specific types of damage to maintain genomic stability (Schärer, O. D. 2013. Cold Spring Harbor Perspectives in Biology). Deficiencies in the repair of these lesions are directly linked to severe genetic disorders such as Xeroderma pigmentosum, which is characterized by an extreme predisposition to skin cancers (DiGiovanna, J. J., & Kraemer, K. H. 2012. Journal of Investigative Dermatology). In a therapeutic context, these lesions are the focus of DNA repair-enhancing agents, such as topical liposomal T4 endonuclease V, which aims to accelerate the removal of CPDs to prevent skin cancer in high-risk individuals (Dremel, J., et al. 2001. The Lancet). Conversely, the NER pathway itself is sometimes targeted for inhibition to enhance the efficacy of DNA-damaging chemotherapeutic agents like cisplatin, which creates similar bulky adducts (Spivak, G. 2015. Archives of Toxicology).
Nucleotide excision repair (NER) involves the recognition of bulky DNA lesions by proteins like XPC or the RNA polymerase II complex, followed by dual incision of the damaged strand by XPF and XPG nucleases, removal of the damaged oligonucleotide, and gap-filling DNA synthesis by DNA polymerases (Marteijn, J. A., et al. 2014. Nature Reviews Molecular Cell Biology).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Genomic DNA lesions processed by nucleotide excision repair (NER-processed DNA lesions).